Amarin Corp Plcuk (AMRN) Non-Current Assets (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Non-Current Assets of $19.8 million for Q1 2026, down 76.08% year-over-year from $82.6 million in Q1 2025, and down 5.4% quarter-over-quarter from $20.9 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Non-Current Assets (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Non-Current Assets data on file, last reported at $19.8 million in Q1 2026.
- Non-Current Assets for Q1 2026 came in at $19.8 million, down 76.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $135.5 million (down 63.49% YoY), and the FY2025 annual result was $20.9 million, down 76.77% from the prior year.
- Non-Current Assets retreated to $19.8 million in Q1 2026 per AMRN's latest filing, from $20.9 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $254.1 million in Q2 2022 and troughed at $19.8 million in Q1 2026.
- A 5-year average of $120.1 million and a median of $102.1 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets surged 418.74% in 2022, then sank 76.77% in 2025.
- A 5-year view of Non-Current Assets shows it stood at $197.1 million in 2022, then plunged by 45.86% to $106.7 million in 2023, then decreased by 15.7% to $90.0 million in 2024, then slumped by 76.77% to $20.9 million in 2025, then decreased by 5.4% to $19.8 million in 2026.
- Business Quant data shows AMRN's Non-Current Assets at $19.8 million in Q1 2026, $20.9 million in Q4 2025, and $31.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 60.81 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 61.74 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 141.72 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 102.93 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 125.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 61.03 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 37.64 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 165.18 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 59.27 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | 19.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.76 Mn |
| Dec 31, 2025 | 20.89 Mn |
| Sep 30, 2025 | 31.51 Mn |
| Jun 30, 2025 | 63.33 Mn |
| Mar 31, 2025 | 82.64 Mn |
| Dec 31, 2024 | 89.95 Mn |
| Sep 30, 2024 | 100.40 Mn |
| Jun 30, 2024 | 98.10 Mn |
| Mar 31, 2024 | 102.11 Mn |
| Dec 31, 2023 | 106.70 Mn |
| Sep 30, 2023 | 121.52 Mn |
| Jun 30, 2023 | 153.52 Mn |
| Mar 31, 2023 | 176.39 Mn |
| Dec 31, 2022 | 197.08 Mn |
| Sep 30, 2022 | 221.78 Mn |
| Jun 30, 2022 | 254.14 Mn |
| Mar 31, 2022 | 201.09 Mn |
| Dec 31, 2021 | 189.34 Mn |
| Sep 30, 2021 | 72.77 Mn |
| Jun 30, 2021 | 48.99 Mn |